Manufacturing News
Takeda and Innovent Strike $1.2B Deal for Cancer Pipeline
Takeda Pharmaceutical Company has entered a global strategic partnership with China’s Innovent Biologics to acquire rights to two late-stage investigational oncology medicines and an option on an early-stage program, the companies announced October 22. Under the agreement, Takeda will pay
22 October 2025